Optimizing Antiplatelet Therapy in Coronary Interventions

antiplatelet therapy in hemodialysis patients undergoing percutaneous coronary interventions

conclusions this investigation might contribute to delineate the best treatment options for this high risk population. evidence acquisition we reviewed current evidences on the use of antiplatelet therapy in patients with esrd/hd undergoing pci, focusing on the efficacy and safety of specific agents and their indications for detailed clinical settings. results clinical setting in hd patients is...

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions

CONTEXT Coronary artery disease is highly prevalent among patients with end stage renal disease/hemodialysis (ESRD/HD) and coronary percutaneous interventions (PCI) has been increased by nearly 50% over the past decade. After PCI with stent placement, guidelines recommend dual antiplatelet therapy (DAPT), but no specifically tailored pharmacotherapy approach is outlined for this frail populatio...

Dual antiplatelet therapy in acute coronary syndromes and coronary artery interventions.

Optimization of platelet inhibition in patients with acute coronary syndromes reduces the risk for ischemic events, but at the same time increases the risk for bleeding. There are several predictors of bleeding risk in patients with acute coronary syndromes. These include demographic variables such as advanced age, female gender, low body weight, concomitant diseases such as diabetes,renal insu...

Monitoring and optimizing antiplatelet therapy in patients undergoing percutaneous coronary intervention

Dual Antiplatelet Therapy in Percutaneous Coronary Intervention

In 2016, dual antiplatelet therapy (DAPT) assumes its 20th anniversary since the publication of the first randomized clinical trial establishing the superiority of DAPT over anticoagulant therapy among patients undergoing percutaneous coronary intervention (PCI) (Figure). Because then, both antiplatelet therapy and PCI have undergone continued refinement. Clopidogrel substituted ticlopidine, an...